Impact of Phase II Trials on Survival in Anaplastic Gliomas
Author Information
Author(s): Levin Victor A, Ictech Sandra, Hess Kenneth R
Primary Institution: The University of Texas M. D. Anderson Cancer Center
Hypothesis
Is progression-free survival (PFS) an appropriate end-point for phase II trials for anaplastic gliomas and how does it impact phase III trials?
Conclusion
Progression-free survival is a more reliable end-point than overall survival for evaluating chemotherapy effectiveness in patients with anaplastic gliomas.
Supporting Evidence
- PFS rates at 6, 9, and 12 months were significantly different between treatment groups.
- 80% of patients at recurrence had a 23% likelihood of living more than 1 year with each chemotherapy.
- Age and treatment group membership were significant factors affecting PFS.
Takeaway
This study shows that measuring how long patients live without their cancer getting worse is a better way to see if a treatment works than just looking at how long they live overall.
Methodology
Data from 16 phase II studies were combined and analyzed to assess progression-free survival at 6, 9, and 12 months.
Potential Biases
Potential bias due to the retrospective nature of the data collection and exclusion criteria.
Limitations
The study excluded patients with anaplastic ependymoma and those with AOs, which may limit the generalizability of the findings.
Participant Demographics
Patients included were diagnosed with anaplastic gliomas, with a mean age of approximately 41 years and a Karnofsky performance score of around 84.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website